LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

Search

Twist Bioscience Corp

Closed

SectorHealthcare

54.89 4.21

Overview

Share price change

24h

Current

Min

52.41

Max

57.73

Key metrics

By Trading Economics

Income

-3.4M

-31M

Sales

4.7M

104M

Profit margin

-29.419

Employees

979

EBITDA

-3.2M

-24M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+5.88% upside

Dividends

By Dow Jones

Next Earnings

4 May 2026

Market Stats

By TradingEconomics

Market Cap

409M

3B

Previous open

50.68

Previous close

54.89

News Sentiment

By Acuity

50%

50%

165 / 351 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Twist Bioscience Corp Chart

Past performance is not a reliable indicator of future results.

Related News

18 Feb 2026, 22:31 UTC

Earnings

Brambles Raises Dividend, Cash-Flow Guidance as 1st Half Profit Jumps -- Update

18 Feb 2026, 22:18 UTC

Earnings

Wal-Mart de Mexico 4Q Profit Falls, Hit by Higher Taxes

18 Feb 2026, 22:11 UTC

Earnings

Wesfarmers Boosts Dividend After 1st Half Profit Rises -- Update

18 Feb 2026, 21:52 UTC

Earnings

Telstra Boosts Dividend as First-Half Earnings Rise 5.5% -- Update

18 Feb 2026, 23:56 UTC

Market Talk

Santos's Review of Domestic Assets Could Lead to Simpler Portfolio -- Market Talk

18 Feb 2026, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

18 Feb 2026, 23:46 UTC

Market Talk

Nikkei May Rise After U.S. Tech Stock Gains -- Market Talk

18 Feb 2026, 23:34 UTC

Market Talk
Earnings

Brambles' Cost Control Stands Out to Bull -- Market Talk

18 Feb 2026, 23:33 UTC

Market Talk

Gold Edges Higher Amid Growing Risks of U.S.-Iran Conflict -- Market Talk

18 Feb 2026, 23:32 UTC

Market Talk

Australia Jobs Data Will Likely Support May Hike Assumptions -- Market Talk

18 Feb 2026, 22:45 UTC

Earnings

DoorDash Stock Rebounds. Earnings and Revenue Both Fall Short. -- Barrons.com

18 Feb 2026, 22:44 UTC

Market Talk

Investors Eyeing Nvidia's Revenue Visibility Ahead of 4Q Print -- Market Talk

18 Feb 2026, 22:37 UTC

Earnings

Nutrien 4Q EPS $1.18 >NTR.T

18 Feb 2026, 22:37 UTC

Earnings

Nutrien 4Q Sales $5.34B >NTR.T

18 Feb 2026, 22:35 UTC

Earnings

Pan American Silver 4Q EPS $1.07 >PAAS

18 Feb 2026, 22:35 UTC

Earnings

Pan American Silver 4Q Rev $1.18B >PAAS

18 Feb 2026, 22:30 UTC

Earnings

Kinross Gold Raises Quarterly Dividend to 4c Vs. 3.5c >K.T

18 Feb 2026, 22:29 UTC

Earnings

Kinross Gold 4Q EPS 75c >K.T

18 Feb 2026, 22:22 UTC

Earnings

Coeur Mining: Full-Yr 2026 Production Is Expected to Be 55,000 - 65,000 Ounces of Gold and 5.5M - 6.3M Ounces of Silver >CDE

18 Feb 2026, 22:22 UTC

Market Talk

Nvidia 4Q Earnings Coming Amid China Export Battle -- Market Talk

18 Feb 2026, 22:16 UTC

Earnings

Brambles Raises Dividend, Cash-Flow Guidance as 1H Profit Jumps -- Update

18 Feb 2026, 22:05 UTC

Earnings

Pan American Silver Reports Record Fourth Quarter And Full Year 2025 Financial Results; Record Cash Flow From Operations Of $554 Million In The Fourth Quarter; Dividend Increased By 29% >PAAS

18 Feb 2026, 22:03 UTC

Earnings

Kaiser Aluminum Expects to Improve Conversion Rev by 5% to 10% and Adj EBITDA by 5% to 15% for FY26 >KALU

18 Feb 2026, 22:02 UTC

Earnings

Kaiser Aluminum 4Q Adj EPS $1.53 >KALU

18 Feb 2026, 22:02 UTC

Earnings

Kaiser Aluminum 4Q Sales $929M >KALU

18 Feb 2026, 22:02 UTC

Earnings

Kaiser Aluminum 4Q EPS $1.68 >KALU

18 Feb 2026, 22:00 UTC

Earnings

Kinross Gold 4Q Adj EPS 67c >KGC

18 Feb 2026, 22:00 UTC

Earnings

Kinross Gold 4Q Sales $2.02B >KGC

18 Feb 2026, 21:56 UTC

Earnings

Wesfarmers Boosts Dividend After 1H Profit Rises -- Update

18 Feb 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

Peer Comparison

Price change

Twist Bioscience Corp Forecast

Price Target

By TipRanks

5.88% upside

12 Months Forecast

Average 52 USD  5.88%

High 58 USD

Low 50 USD

Based on 6 Wall Street analysts offering 12 month price targets forTwist Bioscience Corp - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

6

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

31.56 / 38.6884Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

165 / 351 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Twist Bioscience Corp

Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, it offers synthetic SARS-CoV-2 RNA reference sequences as positive controls to develop both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company has a strategic collaboration with bitBiome Inc. The company was incorporated in 2013 and is headquartered in South San Francisco, California.
help-icon Live chat